Secretin infusion decreases food intake in healthy men-a randomized, placebo-controlled, double-blind, crossover study

What Was Tested

The paper reports a study of Secretin, published as a randomized controlled trial.

Who Took Part

According to the abstract, 25 men were involved.

By PubMed's age tags, the people studied were young adults and adults, men only.

The researchers investigated the effects of exogenous secretin on ad libitum food intake, BAT activity, and postprandial physiology in healthy male volunteers.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

The men were allocated by chance, so the Secretin group and the comparison group should start out alike.

As a double-blind Secretin study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Secretin group a baseline to be compared against.

Each person switched between Secretin and the comparison at some point, usually with a gap in between.

The hormone secretin, best known for regulating pH in the duodenum, has anorectic properties in mice proposedly mediated via secretin-induced brown adipose tissue (BAT) activation.

After 30 min of infusion, a standardized liquid-mixed meal was ingested, and after 5 h, food intake and meal duration were assessed during an ad libitum meal test.

Brown adipose tissue activity was assessed regularly by thermal imaging-measured supraclavicular skin temperature.

What Was Measured

Topics PubMed links to this paper include Secretin, Eating, Postprandial Period, Healthy Volunteers, Adipose Tissue, Brown and Gastric Emptying.

The authors tagged it with the keywords brown adipose tissue, gastrointestinal tract, lipid metabolism, mechanisms in endocrinology and obesity.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Secretin in 25 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (European journal of endocrinology), a journal based in England.

More context: the Secretin compound page, all human trials.